The oversubscribed round was backed by MMC Ventures, Molten VC, Simplyhealth Ventures, and KHP Ventures.
"Today’s announcement of our heavily oversubscribed investment round is a major endorsement of our incredible technology and our journey to date. We are delighted to see such healthy interest in our vision of revolutionising access to screening from the investment community and we’re thrilled to have Molten Ventures, MMC Ventures, and Simplyhealth Ventures investing. The inclusion of KHP Ventures as a fund backed by NHS institutions is a clear signal of our NHS traction and alignment with overall NHS priorities – we couldn’t be happier that they’re investing in our journey."
The Y Combinator alumnus has raised capital from Molten Ventures, Hummingbird, and Amino Collective to scale its clinical operating system.
"We’re excited to bring Inga of Molten on our journey. From day one, it was clear to us that she shared our vision of care enablement, a thesis Inga and Molten have had for years. I’m deeply grateful for the special crew we have at Anima. This is a passion project – we’re building what we wish we had as doctors and patients. No one is here just to do a job. We all serve a greater purpose – and that’s why ultimately we’ll continue to move mountains."
The financing round was led by Molten Ventures with backing from LifeX Ventures and private individuals.
"With our technology, we’re building the world’s largest immune data assets across health and disease, which allows us to perform analyses with a level of depth and granularity that was previously unthinkable. This systems-level approach to understanding immune function enables us to look at the bigger picture rather than just focusing on individual disease-associated parameters. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run."
— Adam Laing, President and Chief Scientific Officer
The investment round was led by Molten Ventures with backing from Stride VC and Alumni Ventures.
"From the very beginning, our vision for Oliva has been clear: to be Europe’s most comprehensive and clinically validated workplace mental health platform. Companies working with Oliva get more than a platform – they get a full-scale partnership for their employee mental health strategy. And for employees – they don’t get short changed by a system powered by bots. We offer evidence-led, human-centric support strategies that are tailored to their individual needs."
The round was led by Molten Ventures to fund commercialisation ahead of the company's first satellite launch.
"We’re leading SatelliteVu’s funding round as it prepares for its June launch. Their unique technology tackles key climate issues, and we’re impressed with their commercial progress. Their $160m in early commitments is a stellar model of pre-launch sales for deep-tech companies, which other climate-tech firms could emulate."
